A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for those Patients whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations (Alliance A031701)
      Google Scholar   
Citation:
J Clin Oncol vol 40 (16_suppl) TPS4615-TPS4615
Meeting Instance:
ASCO 2022
Year:
2022
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
No-Endpoint
Analysis:
Trial-Description-Only
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
No
SDC:
Yes
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882  
Corr. Author:
 
Authors:
                   
Networks:
LAPS-NY016, MD015, MO036, SANFORD   
Study
Alliance-A031701
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: